|
US9937531B2
(en)
|
2009-03-10 |
2018-04-10 |
Bookit Oy Ajanvarauspalvelu |
Method and system for delivery of goods
|
|
EP1469833B1
(en)
|
2002-02-01 |
2021-05-19 |
Bend Research, Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
|
US7375134B2
(en)
|
2002-03-05 |
2008-05-20 |
Axys Pharmaceuticals, Inc. |
Cathepsin cysteine protease inhibitors
|
|
WO2003077948A1
(fr)
*
|
2002-03-19 |
2003-09-25 |
Kowa Co., Ltd. |
Myelome : medicaments preventifs/curatifs et methode de diagnostic
|
|
CN1809536A
(zh)
*
|
2003-04-24 |
2006-07-26 |
麦克公司 |
Akt活性抑制剂
|
|
AU2004266740B2
(en)
*
|
2003-08-21 |
2010-08-26 |
Merck Frosst Canada Ltd |
Cathepsin cysteine protease inhibitors
|
|
CN1842515A
(zh)
*
|
2003-08-27 |
2006-10-04 |
默克弗罗斯特加拿大有限公司 |
组织蛋白酶抑制剂
|
|
DK1663958T3
(da)
*
|
2003-09-18 |
2015-04-07 |
Virobay Inc |
Haloalkylholdige forbindelser som cysteinproteasehæmmere
|
|
EP1682524A1
(en)
*
|
2003-10-24 |
2006-07-26 |
Aventis Pharmaceuticals, Inc. |
Novel keto-oxadiazole derivatives as cathepsin inhibitors
|
|
CA2548600A1
(en)
*
|
2003-12-12 |
2005-06-23 |
Merck Frosst Canada & Co. |
Cathepsin cysteine protease inhibitors
|
|
CA2552713A1
(en)
*
|
2004-01-08 |
2005-07-21 |
Merck Frosst Canada & Co. |
Cathepsin cysteine protease inhibitors
|
|
US7429674B2
(en)
|
2004-04-14 |
2008-09-30 |
Merck & Co. Inc.. |
Process for preparing fluoroleucine alkyl esters
|
|
AU2005271620B2
(en)
*
|
2004-08-04 |
2011-03-24 |
Merck Frosst Canada Ltd |
Diastereoselective reductive amination process
|
|
JP2008513472A
(ja)
*
|
2004-09-17 |
2008-05-01 |
バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト |
システインプロテアーゼインヒビターの調製のための方法及び中間体
|
|
TW200619206A
(en)
*
|
2004-09-29 |
2006-06-16 |
Anormed Inc |
Chemokine-binding heterocyclic compound salts, and methods of use thereof
|
|
AR055283A1
(es)
*
|
2004-11-23 |
2007-08-15 |
Merck Frosst Canada Ltd |
Inhibidores de cisteinproteasa de catepsina
|
|
WO2006060494A1
(en)
|
2004-12-01 |
2006-06-08 |
Schering Aktiengesellschaft |
Haloalkyl containing compounds as cysteine protease inhibitors
|
|
WO2006060810A1
(en)
|
2004-12-02 |
2006-06-08 |
Schering Aktiengesellschaft |
Sulfonamide compounds as cysteine protease inhibitors
|
|
EP1841730A4
(en)
*
|
2005-01-19 |
2010-10-27 |
Merck Frosst Canada Ltd |
CATHEPSIN K INHIBITORS AND ATHEROSCLEROSIS
|
|
US20090005323A1
(en)
*
|
2005-01-19 |
2009-01-01 |
Michael David Percival |
Cathepsin K Inhibitors and Obesity
|
|
US20080138635A1
(en)
*
|
2005-03-02 |
2008-06-12 |
Zhikuan Chen |
Conjugated Organic Molecules for Molecular Electronic Devices
|
|
AU2006302797B2
(en)
*
|
2005-03-02 |
2012-02-02 |
Merck Canada Inc. |
Composition for inhibition of cathepsin K
|
|
US7488848B2
(en)
*
|
2005-03-21 |
2009-02-10 |
Virobay, Inc. |
Alpha ketoamide compounds as cysteine protease inhibitors
|
|
JP5215167B2
(ja)
*
|
2005-03-22 |
2013-06-19 |
ビロベイ，インコーポレイティド |
システインプロテアーゼ阻害剤としてのスルホニル基含有化合物
|
|
EP1891003A4
(en)
|
2005-06-02 |
2010-07-21 |
Merck Frosst Canada Ltd |
FLUORALKYLAMINE DERIVATIVES AS CATHEPSIN INHIBITORS
|
|
CA2615991C
(en)
|
2005-07-19 |
2011-02-08 |
Daiichi Sankyo Company, Limited |
Substituted propanamide derivative and pharmaceutical composition comprising the same
|
|
WO2007012180A1
(en)
*
|
2005-07-26 |
2007-02-01 |
Merck Frosst Canada Ltd. |
Papain family cysteine protease inhibitors for the treatment of parasitic diseases
|
|
DK2032535T3
(da)
*
|
2006-06-01 |
2012-11-05 |
Sanofi Sa |
Spiro-cycliske nitriler som protease-inhibitorer
|
|
US7622593B2
(en)
*
|
2006-06-27 |
2009-11-24 |
The Procter & Gamble Company |
Human protein tyrosine phosphatase inhibitors and methods of use
|
|
US7893112B2
(en)
*
|
2006-10-04 |
2011-02-22 |
Virobay, Inc. |
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
EP2079683B1
(en)
*
|
2006-10-04 |
2015-01-21 |
Virobay, Inc. |
Di-fluoro containing compounds as cysteine protease inhibitors
|
|
KR101578674B1
(ko)
*
|
2006-12-29 |
2015-12-18 |
아비에 도이치란트 게엠베하 운트 콤파니 카게 |
카복스아미드 화합물 및 칼페인 억제제로서의 이의 용도
|
|
WO2008106059A1
(en)
|
2007-02-26 |
2008-09-04 |
Merck & Co., Inc. |
Formulations for cathepsin k inhibitors
|
|
US8273913B2
(en)
|
2007-04-02 |
2012-09-25 |
Merck Canada Inc. |
Amidation process for the preparation of cathepsin K inhibitors
|
|
KR20100023948A
(ko)
|
2007-06-08 |
2010-03-04 |
닛뽕 케미파 가부시키가이샤 |
뇌동맥류의 치료 또는 예방약
|
|
JPWO2009054454A1
(ja)
|
2007-10-24 |
2011-03-03 |
国立大学法人 東京医科歯科大学 |
カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
|
|
JP5511676B2
(ja)
*
|
2007-11-29 |
2014-06-04 |
メルク カナダ インコーポレイテッド |
寄生虫疾患を治療するためのシステインプロテアーゼ阻害剤
|
|
JPWO2009096198A1
(ja)
*
|
2008-02-01 |
2011-05-26 |
一般社団法人ファルマＩｐ |
新規ビアリール誘導体
|
|
EP2262370A4
(en)
*
|
2008-04-01 |
2011-08-31 |
Virobay Inc |
DIFLUOROUS COMPOUNDS AS A CYSTONE PROTEASE INHIBITOR
|
|
WO2009125861A1
(ja)
*
|
2008-04-09 |
2009-10-15 |
帝人ファーマ株式会社 |
システインプロテアーゼ阻害剤
|
|
US20110065800A1
(en)
*
|
2008-05-14 |
2011-03-17 |
Haihong Fan |
Formulations for cathepsin k inhibitors
|
|
SI2421826T1
(sl)
*
|
2009-04-20 |
2014-02-28 |
F. Hoffmann-La Roche Ag |
Derivati prolina kot inhibitorji katepsina
|
|
US8324417B2
(en)
|
2009-08-19 |
2012-12-04 |
Virobay, Inc. |
Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
|
|
US9051304B2
(en)
*
|
2009-12-22 |
2015-06-09 |
AbbVie Deutschland GmbH & Co. KG |
Carboxamide compounds and their use as calpain inhibitors V
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2012112363A1
(en)
*
|
2011-02-14 |
2012-08-23 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
EP2681188A4
(en)
*
|
2011-03-02 |
2015-04-15 |
Merck Sharp & Dohme |
amidation
|
|
US8680152B2
(en)
|
2011-05-02 |
2014-03-25 |
Virobay, Inc. |
Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain
|
|
CN103687593B
(zh)
|
2011-05-16 |
2016-09-28 |
拜耳知识产权有限责任公司 |
组织蛋白酶k抑制用于治疗和/或预防肺动脉高压和/或心力衰竭的用途
|
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
US20140199495A1
(en)
|
2013-01-11 |
2014-07-17 |
Floor Iptech Ab |
Digital printing and embossing
|
|
BR112015018882B1
(pt)
|
2013-02-19 |
2021-09-14 |
Novartis Ag |
Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
|
|
SG10201707409PA
(en)
|
2013-03-13 |
2017-10-30 |
Forma Therapeutics Inc |
Novel compounds and compositions for inhibition of fasn
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
US20160106679A1
(en)
|
2013-05-16 |
2016-04-21 |
Sandoz Ag |
Tablet with increased drug load of odanacatib
|
|
EP2808012A1
(en)
|
2013-05-29 |
2014-12-03 |
ratiopharm GmbH |
Method for producing dosage form comprising odanacatib
|
|
JP6226437B2
(ja)
|
2013-06-14 |
2017-11-08 |
生化学工業株式会社 |
α−オキソアシルアミノカプロラクタム体
|
|
EP3009444B1
(en)
|
2013-06-14 |
2017-12-20 |
Seikagaku Corporation |
Alpha-oxoacyl amino-caprolactam derivative
|
|
EP3019468A4
(en)
*
|
2013-07-11 |
2017-01-11 |
Merck Sharp & Dohme Corp. |
Formulations for cathepsin k inhibitors with vitamin d
|
|
WO2015054089A1
(en)
*
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
JP6523303B2
(ja)
|
2014-01-17 |
2019-05-29 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CZ2014941A3
(cs)
|
2014-12-19 |
2016-06-29 |
Zentiva, K.S. |
Příprava vysoce čistého intermediátu pro syntézu Odanacatibu
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
RU2017134379A
(ru)
|
2015-03-25 |
2019-04-03 |
Новартис Аг |
Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
CN112625028B
(zh)
|
2015-06-19 |
2024-10-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
ES2741746T3
(es)
|
2015-06-19 |
2020-02-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
WO2017036357A1
(zh)
*
|
2015-08-29 |
2017-03-09 |
广东东阳光药业有限公司 |
组织蛋白酶k抑制剂及其用途
|
|
CN108368056A
(zh)
*
|
2015-11-26 |
2018-08-03 |
豪夫迈·罗氏有限公司 |
锥虫抑制剂
|
|
CN106866502B
(zh)
*
|
2015-12-10 |
2020-10-09 |
广东东阳光药业有限公司 |
组织蛋白酶k抑制剂及其用途
|
|
JP6969800B2
(ja)
|
2016-05-04 |
2021-11-24 |
ジェノシアンス ファルマ |
増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
|
|
MX383856B
(es)
|
2016-06-14 |
2025-03-14 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de shp2.
|
|
MA47380A
(fr)
*
|
2017-01-24 |
2021-03-17 |
Astellas Pharma Inc |
Composé de prolineamide substitué par un phényldifluorométhyle
|
|
KR101916396B1
(ko)
|
2017-02-20 |
2018-11-08 |
서울대학교 산학협력단 |
항암제 또는 항균제로 사용될 수 있는 단백질분해효소 저해제
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
WO2019051469A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
|
FI4046987T3
(fi)
|
2017-12-05 |
2025-10-03 |
Academisch Ziekenhuis Leiden |
Katepsiini-inhibiittoreita
|
|
NL2020021B1
(en)
*
|
2017-12-05 |
2019-06-13 |
Academisch Ziekenhuis Leiden |
Cathepsin inhibitors
|
|
AU2019243099B2
(en)
|
2018-03-28 |
2022-04-07 |
Hanlim Pharmaceutical Co., Ltd. |
2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
JP7542538B2
(ja)
|
2018-09-18 |
2024-08-30 |
ニカング セラピューティクス， インコーポレイテッド |
Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体
|
|
WO2020068873A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
AU2019346550A1
(en)
|
2018-09-25 |
2021-04-22 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
JP2022502385A
(ja)
|
2018-09-29 |
2022-01-11 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための化合物の製造方法
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
US10793554B2
(en)
|
2018-10-29 |
2020-10-06 |
Forma Therapeutics, Inc. |
Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
AU2020250933A1
(en)
|
2019-04-05 |
2021-10-28 |
Centre Hospitalier Régional Et Universitaire De Brest |
Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4013749B1
(en)
|
2019-08-15 |
2026-03-11 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
CN114539111A
(zh)
*
|
2020-11-19 |
2022-05-27 |
深圳信立泰药业股份有限公司 |
奥当卡替的盐及其制备方法和医药用途
|
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
CN119053595A
(zh)
|
2022-03-28 |
2024-11-29 |
尼坎治疗公司 |
作为细胞周期蛋白依赖性激酶2抑制剂的磺酰氨基衍生物
|
|
EP4536363A1
(en)
|
2022-06-08 |
2025-04-16 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
JP2025537123A
(ja)
|
2022-11-11 |
2025-11-14 |
ニカング セラピューティクス， インコーポレイテッド |
ユビキチンプロテアソーム経路を介してサイクリン依存性キナーゼ２を分解するための２，５－置換ピリミジン誘導体を含有する二官能性化合物
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2025117616A1
(en)
|
2023-11-27 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|